Introduction – Company Background
GuangXin Industrial Co., Ltd. is a specialized manufacturer dedicated to the development and production of high-quality insoles.
With a strong foundation in material science and footwear ergonomics, we serve as a trusted partner for global brands seeking reliable insole solutions that combine comfort, functionality, and design.
With years of experience in insole production and OEM/ODM services, GuangXin has successfully supported a wide range of clients across various industries—including sportswear, health & wellness, orthopedic care, and daily footwear.
From initial prototyping to mass production, we provide comprehensive support tailored to each client’s market and application needs.
At GuangXin, we are committed to quality, innovation, and sustainable development. Every insole we produce reflects our dedication to precision craftsmanship, forward-thinking design, and ESG-driven practices.
By integrating eco-friendly materials, clean production processes, and responsible sourcing, we help our partners meet both market demand and environmental goals.
Core Strengths in Insole Manufacturing
At GuangXin Industrial, our core strength lies in our deep expertise and versatility in insole and pillow manufacturing. We specialize in working with a wide range of materials, including PU (polyurethane), natural latex, and advanced graphene composites, to develop insoles and pillows that meet diverse performance, comfort, and health-support needs.
Whether it's cushioning, support, breathability, or antibacterial function, we tailor material selection to the exact requirements of each project-whether for foot wellness or ergonomic sleep products.
We provide end-to-end manufacturing capabilities under one roof—covering every stage from material sourcing and foaming, to precision molding, lamination, cutting, sewing, and strict quality control. This full-process control not only ensures product consistency and durability, but also allows for faster lead times and better customization flexibility.
With our flexible production capacity, we accommodate both small batch custom orders and high-volume mass production with equal efficiency. Whether you're a startup launching your first insole or pillow line, or a global brand scaling up to meet market demand, GuangXin is equipped to deliver reliable OEM/ODM solutions that grow with your business.
Customization & OEM/ODM Flexibility
GuangXin offers exceptional flexibility in customization and OEM/ODM services, empowering our partners to create insole products that truly align with their brand identity and target market. We develop insoles tailored to specific foot shapes, end-user needs, and regional market preferences, ensuring optimal fit and functionality.
Our team supports comprehensive branding solutions, including logo printing, custom packaging, and product integration support for marketing campaigns. Whether you're launching a new product line or upgrading an existing one, we help your vision come to life with attention to detail and consistent brand presentation.
With fast prototyping services and efficient lead times, GuangXin helps reduce your time-to-market and respond quickly to evolving trends or seasonal demands. From concept to final production, we offer agile support that keeps you ahead of the competition.
Quality Assurance & Certifications
Quality is at the heart of everything we do. GuangXin implements a rigorous quality control system at every stage of production—ensuring that each insole meets the highest standards of consistency, comfort, and durability.
We provide a variety of in-house and third-party testing options, including antibacterial performance, odor control, durability testing, and eco-safety verification, to meet the specific needs of our clients and markets.
Our products are fully compliant with international safety and environmental standards, such as REACH, RoHS, and other applicable export regulations. This ensures seamless entry into global markets while supporting your ESG and product safety commitments.
ESG-Oriented Sustainable Production
At GuangXin Industrial, we are committed to integrating ESG (Environmental, Social, and Governance) values into every step of our manufacturing process. We actively pursue eco-conscious practices by utilizing eco-friendly materials and adopting low-carbon production methods to reduce environmental impact.
To support circular economy goals, we offer recycled and upcycled material options, including innovative applications such as recycled glass and repurposed LCD panel glass. These materials are processed using advanced techniques to retain performance while reducing waste—contributing to a more sustainable supply chain.
We also work closely with our partners to support their ESG compliance and sustainability reporting needs, providing documentation, traceability, and material data upon request. Whether you're aiming to meet corporate sustainability targets or align with global green regulations, GuangXin is your trusted manufacturing ally in building a better, greener future.
Let’s Build Your Next Insole Success Together
Looking for a reliable insole manufacturing partner that understands customization, quality, and flexibility? GuangXin Industrial Co., Ltd. specializes in high-performance insole production, offering tailored solutions for brands across the globe. Whether you're launching a new insole collection or expanding your existing product line, we provide OEM/ODM services built around your unique design and performance goals.
From small-batch custom orders to full-scale mass production, our flexible insole manufacturing capabilities adapt to your business needs. With expertise in PU, latex, and graphene insole materials, we turn ideas into functional, comfortable, and market-ready insoles that deliver value.
Contact us today to discuss your next insole project. Let GuangXin help you create custom insoles that stand out, perform better, and reflect your brand’s commitment to comfort, quality, and sustainability.
🔗 Learn more or get in touch:
🌐 Website: https://www.deryou-tw.com/
📧 Email: shela.a9119@msa.hinet.net
📘 Facebook: facebook.com/deryou.tw
📷 Instagram: instagram.com/deryou.tw
Vietnam sustainable material ODM solutions
Are you looking for a trusted and experienced manufacturing partner that can bring your comfort-focused product ideas to life? GuangXin Industrial Co., Ltd. is your ideal OEM/ODM supplier, specializing in insole production, pillow manufacturing, and advanced graphene product design.
With decades of experience in insole OEM/ODM, we provide full-service manufacturing—from PU and latex to cutting-edge graphene-infused insoles—customized to meet your performance, support, and breathability requirements. Our production process is vertically integrated, covering everything from material sourcing and foaming to molding, cutting, and strict quality control.Latex pillow OEM production in Vietnam
Beyond insoles, GuangXin also offers pillow OEM/ODM services with a focus on ergonomic comfort and functional innovation. Whether you need memory foam, latex, or smart material integration for neck and sleep support, we deliver tailor-made solutions that reflect your brand’s values.
We are especially proud to lead the way in ESG-driven insole development. Through the use of recycled materials—such as repurposed LCD glass—and low-carbon production processes, we help our partners meet sustainability goals without compromising product quality. Our ESG insole solutions are designed not only for comfort but also for compliance with global environmental standards.Taiwan neck support pillow OEM factory
At GuangXin, we don’t just manufacture products—we create long-term value for your brand. Whether you're developing your first product line or scaling up globally, our flexible production capabilities and collaborative approach will help you go further, faster.Thailand orthopedic insole OEM manufacturer
📩 Contact us today to learn how our insole OEM, pillow ODM, and graphene product design services can elevate your product offering—while aligning with the sustainability expectations of modern consumers.High-performance graphene insole OEM Thailand
An agar plate with the human pathogen Pseudomonas aeruginosa (green) and three antibiotics (labeled A, B and C). Credit: Roderich Roemhild Understanding resistance rates and cross-resistance can improve the potency of sequential antibiotic treatment protocols. Sequential treatment using antibiotics that are similar but swapped around frequently is an effective way to kill bacteria and prevent drug resistance, a study in eLife reports. The results challenge a broad assumption that using similar antibiotics promotes cross-resistance to drugs, and show that available antibiotics could offer unexplored, highly potent treatment options. “We are currently in an antibiotic crisis, where the overuse of antibiotics is leading to increased antibiotic resistance and certain infections have become difficult and even impossible to treat,” says first author Aditi Batra, a graduate student at the Max Planck Institute for Evolutionary Biology and the University of Kiel, Germany. “It is the ability of pathogens to evolve and adapt to drugs that underlies this resistance, but evolutionary theory predicts that adaptation is difficult when the environment changes rapidly. We wanted to test if we could use sequential antibiotic treatment to slow down the evolution of human pathogens and limit drug resistance.” The team used bacteria called Pseudomonas aeruginosa (P. aeruginosa), which can cause pneumonia and other infections in humans. They tested three different sequences of antibiotics under laboratory conditions and measured their potency at killing off different sub-populations of evolved bacterial cells. Two sets of antibiotics belonged to a class of drugs called ß-lactams, which have a common structural component – a ß-lactam ring. The other set of antibiotics all worked by different mechanisms. To the team’s surprise, treatment with both sets of ß-lactam antibiotics was better at killing off bacterial populations than some of the unrelated antibiotics. Moreover, switching rapidly between the individual antibiotics produced much better extinction of bacterial populations than when the switch between antibiotics was slower. This suggests that fast switching between antibiotics constrained the bacteria’s ability to adapt to the drugs. Given this unexpected result, the team explored the mechanisms that cause this evolutionary constraint. They studied the changes in growth, resistance profiles and whole genome sequences of the P. aeruginosa populations treated with the most potent sequence of ß-lactam antibiotics, which combined carbenicillin, doripenem and cefsulodin. They noted that when the sequences were switched quickly, bacterial growth during a switch to doripenem was much lower than for the other two antibiotics, indicating that resistance to this drug might emerge more slowly. They also looked at whether physiological changes that occur as a result of drug treatment made the bacteria resistant or more susceptible to the other drugs in the sequence. They found that spontaneous development of resistance was much lower for doripenem than the other two drugs. There was also less cross-resistance towards this drug than the other two antibiotics. This lack of cross-resistance may indicate the presence of so-called collateral sensitivity; this means that the mutant cells, which have become resistant to one drug, maintain at least ancestral levels of susceptibility against the second drug. Collateral sensitivity is known to be important for the effectiveness of sequential treatment. “Although sequential treatments with such similar antibiotics should have sped up resistance evolution, we found this is not the case if resistance to one of the antibiotics cannot emerge easily, and if the antibiotics show collateral sensitivity to each other,” says senior author Hinrich Schulenburg, Fellow of the Max Planck Institute for Evolutionary Biology and Professor at the University of Kiel. “It is ironic that the differential cross-resistance profile of the ß-lactam drugs was a key factor to treatment potency, even though this is usually used to reject treatment that exclusively uses these drugs. Our study shows that spontaneous resistance rates of component antibiotics could be used as a guiding principle for sequential treatments and could improve the potency of sequential protocols.” This study has been published as part of ‘Evolutionary Medicine: A Special Issue’ from eLife. To view the Special Issue, visit https://elifesciences.org/collections/8d9426aa/evolutionary-medicine-a-special-issue. Reference: “High potency of sequential therapy with only ß-lactam antibiotics” by Aditi Batra, Roderich Roemhild, Emilie Rousseau, Sören Franzenburg, Stefan Niemann and Hinrich Schulenburg, 28 July 2021, eLife. DOI: 10.7554/eLife.68876
A new paper identifies certain fundamental limits to life. (Ernst Haeckel’s Radiolaria [1862].) Via: Public Domain ReviewA study crossing the boundaries between science fiction and scientific laws explores the potential limits of life as we know it and beyond. It draws on various scientific disciplines to suggest fundamental constraints on the forms life might take, both on Earth and elsewhere. Exploring Extraterrestrial and Artificial Life Extraterrestrial and artificial life have always fascinated humankind. With knowledge rooted in the building blocks of Earth’s biosphere, can we predict how life might exist on other planets? What natural laws or limitations might shape the Frankenstein-like life forms we hope to create in labs? Scientific Limits of Life Forms A study published in Interface Focus by several Santa Fe Institute researchers moves these questions from the realm of science fiction into the realm of science. By examining case studies in thermodynamics, computation, genetics, cellular development, brain science, ecology, and evolution, the researchers identified fundamental limits that make certain forms of life impossible. These limits include the need for systems that reduce entropy (such as the ability to heal or repair), the inevitability of closed-compartment cells as the building blocks of life, and decision-making systems — like brains — that process information through neuron-like components. Universal Logic in Life Systems The authors point to historical examples where people predicted some complex features of life that biologists later confirmed. Examples include the Schrodinger view of information molecules as “aperiodic crystals,” or mid-century simulations predicting that parasites are inevitable when complex life evolves. That such correct predictions were possible with almost no available evidence suggests all living systems follow an underlying universal logic. Reference: “Fundamental constraints to the logic of living systems” by Ricard Solé, Christopher P. Kempes, Bernat Corominas-Murtra, Manlio De Domenico, Artemy Kolchinsky, Michael Lachmann, Eric Libby, Serguei Saavedra, Eric Smith and David Wolpert, 25 October 2024, Interface Focus. DOI: 10.1098/rsfs.2024.0010
Australian researchers have discovered how COVID-19 can infect human placenta, revealing that the virus affects the syncytiotrophoblast cells, which are crucial for maintaining pregnancy. The study also found that anti-ACE2 antibodies and antiviral drugs can effectively prevent this infection, providing a significant advancement in understanding and potentially mitigating the effects of viral infections on pregnancy. Human skin cells reprogrammed into placental stem cells shows how COVID infects placenta — and how it can be stopped. In a landmark study published today (July 13) in the journal Nature Cell Biology, Australian researchers, led by Professor Jose Polo from Monash University and the University of Adelaide and University of Melbourne’s Professor Kanta Subbarao from the Peter Doherty Institute for Infection and Immunity (Doherty Institute), have revealed how COVID-19 can infect the human placenta. Research has shown that COVID-19 infections during pregnancy may lead to adverse outcomes, but little is known about the mechanisms behind the effects of SARS-CoV-2 infection in pregnancy. Placenta cells (syncytiotrophoblast, in green) infected with the SARS-CoV-2 virus (COVID-19, in red); blue areas are cell nuclei labeling the multinucleated syncytiotrophoblasts. Credit: Monash University The Australian research team grew placenta tissue in the lab, using a state-of-the-art method developed by Professor Polo and colleagues where human skin cells are “reprogrammed” into trophoblast stem cells (the cells that help a developing embryo attach to the wall of the uterus, forming part of the placenta). They found that ACE2, a protein that acts as the doorway for SARS-CoV-2 to enter organs such as the lung, is present in specific placental cells, like syncytiotrophoblasts (ST cells). Importantly, ST cells were susceptible to the virus – a major finding as these placental cells produce the key hormone for maintaining pregnancy (hCG). Dr. Joseph Chen, a stem cell biologist at Monash University and co-first author of the report, said this discovery explains several clinical reports indicating inflammation of the placenta due to COVID-19. “We observed that SARS-CoV-2 infection led to a significant reduction in the survival and differentiation of ST cells, which in turn resulted in lower production of hCG,” he said. “It suggests that this is how COVID-19 could impact pregnancy, though further investigations are needed.” Professor Jose Polo. Credit: Mike Rutherford Virologist at Doherty Institute and co-first author of the study Dr Jessica Neil said, “our team also discovered that anti-ACE2 antibodies and antiviral drugs were effective in preventing SARS-CoV-2 infection and restoring normal ST differentiation and function”. Professor Subbarao said that this study is a significant advance for the broader understanding of viral infections in pregnancy. “Our study provides valuable insights into the link between SARS-CoV-2 infection and placenta pathology. This is a game changer as we are now equipped to explore how the early placenta may be affected by other viruses as well,” she said. Professor Polo emphasized the importance of the research in establishing a platform to study early placental cell types. “This study not only helps us to understand what happens when the placenta is infected with the COVID-19 virus during pregnancy, it also means we have established a broader, scalable and tractable platform to study early placental cell types,” he said. Reference: “A placental model of SARS-CoV-2 infection reveals ACE2-dependent susceptibility and differentiation impairment in syncytiotrophoblasts” by J. Chen, J. A. Neil, J. P. Tan, R. Rudraraju, M. Mohenska, Y. B. Y. Sun, E. Walters, N. G. Bediaga, G. Sun, Y. Zhou, Y. Li, D. Drew, P. Pymm, W. H. Tham, F. J. Rossello, G. Nie, X. Liu, K. Subbarao and J. M. Polo, 13 July 2023, Nature Cell Biology. DOI: 10.1038/s41556-023-01182-0
DVDV1551RTWW78V
Innovative insole ODM solutions in Taiwan 》flexible, experienced, and ready to support your growthThailand graphene sports insole ODM 》delivering consistent quality from sample to mass productionODM pillow for sleep brands Indonesia 》manufacturing with a focus on sustainability and comfort